Biodesix (BDSX) Consolidated Net Income (2019 - 2026)

Biodesix (BDSX) has 8 years of Consolidated Net Income data on file, last reported at -$8.5 million in Q1 2026.

• Quarterly Consolidated Net Income rose 21.46% year-over-year to -$8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$88.4 million (down 120.83% YoY) and the FY2025 annual result came in at -$134.4 million, down 0.68% from the prior year.
• Consolidated Net Income retreated to -$8.5 million in Q1 2026, from -$4.0 million in the prior quarter.
• In the past five years, Consolidated Net Income ranged from a high of -$4.0 million in Q4 2025 to a low of -$64.6 million in Q1 2023.
• A 5-year average of -$21.6 million and a median of -$13.2 million in 2023 frame the typical range for Consolidated Net Income.
• Annual changes were most pronounced in 2024 — Consolidated Net Income soared 79.04% — and 2025, when it sank 412.78%.
• Tracing BDSX's Consolidated Net Income over 5 years: stood at -$9.4 million in 2022, then tumbled by 40.4% to -$13.2 million in 2023, then surged by 36.19% to -$8.4 million in 2024, then surged by 52.08% to -$4.0 million in 2025, then plunged by 111.1% to -$8.5 million in 2026.
• The last three Consolidated Net Income figures came in at -$8.5 million (Q1 2026), -$4.0 million (Q4 2025), and -$23.7 million (Q3 2025), per Business Quant data.